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The United Kingdom is the first and so far only country to pass explicit legislation allowing for 
the licensed use of a new reproductive 
technology: mitochondrial replacement 
therapy.1 The techniques used in this 
technology may prevent the transmis-
sion of mitochondrial DNA diseases, 
but they are controversial because they 
involve the manipulation of oocytes 
or embryos and the transfer of genetic 
material. Some commentators have 
even suggested that mitochondrial re-
placement therapy constitutes germline 
genome modification, a prospect that 
has long been the subject of ethical con-
cern.2
While the ethical issues raised by 
MRT continue to provoke academic de-
bate, the United Kingdom has already 
granted the first license, of a two-step 
scheme, to Newcastle Fertility Cen-
tre; a second license now needs to be 
granted to a specific patient, which is 
yet to happen.3 Although a 2016 U.S. 
Institute of Medicine report asserted 
that mitochondrial replacement is ethi-
cally permissible as long as it is limit-
ed to male embryos to avoid germline 
transmission, the U.S. Food and Drug 
Administration has been barred from 
even acknowledging the receipt of ap-
plications to carry it out.4 It appears that 
this situation will not change under the 
Trump administration.
Given these antecedents, all eyes were 
on the United Kingdom as the most 
likely location for the first MRT birth, 
so it was a shock to the scientific com-
munity and the world at large when, on 
September 27, 2016, an announcement 
went out that the first baby to result 
from use of the intervention had already 
been born.5 In New York City, United 
States-based scientist John Zhang used 
maternal spindle transfer (one of the 
recognized MRT methods) to gener-
ate five embryos for a woman carrying 
oocytes with deleterious mutations of 
the mitochondrial DNA. Zhang then 
shipped the only euploid embryo to 
Mexico, where it was transferred to the 
mother’s uterus. The baby was born in 
April 2016 and is apparently doing well.
While this is a happy result for the 
new family, the consequences of Zhang’s 
team’s actions—crossing borders to 
achieve an early first in this field—will 
continue to be felt and have implica-
tions for health research in Mexico, the 
reproductive rights of Mexicans, and 
the global politics of science. Medical 
tourism, in which patients travel outside 
the country where they reside to seek 
medical care, has received much ethical 
attention; Zhang’s team’s travel across 
international borders to carry out ex-
perimental procedures represents a form 
of scientific tourism that has not been 
properly ethically explored. It can, how-
ever, have seriously detrimental effects 
for developing countries. An awareness 
of the consequences is essential as we 
continue to contemplate policy in this 
controversial area. 
Local Adverse Effects
The first and most immediate con-cern is the potential for local ad-
verse effects on reproductive health and 
the regulation of research. In Mexico, 
a country with a strong conservative 
vein, embryo research and reproductive 
health are highly contested areas. The 
Catholic church and extensive lobbying 
and protests led by conservative orga-
nizations such as the National Family 
Front have had a significant impact on 
legislators. Since 2007, several state con-
stitutions around the country have been 
changed to protect human life from the 
moment of conception (that is, implan-
tation) or fertilization.6
Access to reproductive health tech-
nologies and scientific research in this 
area are thus already in a precarious 
position. In light of current moves to 
revise and clarify the federal laws gov-
erning assisted reproduction and the use 
of human embryos, the revelation of 
Zhang’s work may be especially damag-
ing.7 The negative publicity directed at 
this event on the international stage and 
the associated vilification of Mexico as 
a country with lax regulation provides 
ammunition to conservative groups 
that are seeking to make the law more 
restrictive.8
Further, an absence of explicit regu-
lation does not necessarily mean “any-
thing goes” or that there is no will to 
regulate. In some cases, a deliberate legal 
lacuna can itself be a form of regulatory 
compromise;9 at other times, regulation 
is a debate in progress, moving forward 
as the result of complex negotiation be-
tween competing positions with high 
political capital. Short-circuiting this 
process by taking advantage of interim 
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uncertainties threatens to disrupt this 
delicate balance and foster a regulatory 
backlash. 
It might be argued that scientific 
tourism can have beneficial effects for 
local science, if the transfer of training 
and technology contribute to local ca-
pacity building. In this case, however, 
given that Zhang’s team intends only 
to transfer the embryos in Mexico while 
carrying out the MRT procedures in 
the United States, this seems unlikely. 
Zhang recently stated that, “[f ]or now, 
our nuclear transfer technique is very 
much like an iPhone that’s designed in 
California and assembled in China.”10 
This does not indicate any intention 
to promote development of Mexican 
science.
Consequences for the Long-Term 
Development of Science
Beyond these immediate consequenc-es, scientific tourism can have wider 
implications for the long-term devel-
opment of science in under-resourced 
destination countries. If regulation be-
comes more restrictive due to scientific 
tourism, local scientists will be unable 
to pursue their research in their home 
country. Given that scientists in these 
countries often lack sufficient resources 
to engage in scientific tourism them-
selves, the net effect will be to block or 
substantively delay their work altogeth-
er, as has happened to the first Mexi-
can scientist to derive an embryonic 
stem-cell line in Mexico.11 The adverse 
impact of this could thus be threefold: 
It contributes to the “brain drain” of 
developing countries, with associated 
negative effects in local scientific com-
munities and health resources. It further 
disadvantages scientists in countries 
where research already lacks support 
or is hampered by unclear regulation. 
And it affects a country’s overall scien-
tific competitiveness in the long term. 
This, obviously, creates a clear problem 
of global scientific injustice.
The response to Zhang’s work also 
reflects a deeper problem of what we 
might call “scientific chauvinism,” 
whereby criteria for scientific practice, 
regulatory standards, and the terms of 
public discourse over science are dic-
tated by the dominant scientific com-
munity. Deviations, which often fall out 
along cultural and political boundaries, 
are automatically classified as unsci-
entific, unethical, or unacceptable.12 
However, Zhang’s work in Mexico does 
not reflect different ethical standards: 
the moral sensitivity of this area of re-
search and the need for regulation and 
oversight is recognized in Mexico, even 
if the response to that need has so far 
been less than effective. Advisory groups 
in both the United Kingdom and the 
United States, along with much of the 
bioethics literature, have deemed the 
technique to be ethically acceptable, 
at least in principle. Zhang’s move to 
Mexico for the embryo transfer process 
was therefore more a matter of escaping 
local oversight than going against ethi-
cal prescriptions. Should blame for this 
be attributed solely to the inadequacy of 
Mexican regulation?
This mode of allocating responsi-
bility for scientists’ conduct reveals a 
problem in attitudes toward global sci-
ence and governance. When ethical 
questions arise about research in devel-
oped countries, the assumption is gen-
erally that the scientist must have done 
something wrong, while the regulatory 
system and scientific culture is only a 
secondary object of scrutiny. The main-
stream coverage of the ethical problems 
that emerged in relation to Paolo Mac-
chiarini’s work on tissue-engineering 
transplants, for example, focused prin-
cipally on his character and actions and 
the individual roles of others who en-
abled his actions, rather than on Swe-
den’s scientific culture and its regulatory 
and governance systems.13
When controversial or ethically du-
bious work is revealed in developing 
countries such as Mexico, however, 
the assumption is often that there is 
something wrong with the system, be 
it insufficient regulation, inadequate 
oversight, or inappropriate ethical stan-
dards. Most commentators took on face 
value Zhang’s statement that, in Mexi-
co, “there are no rules.”14 In fact, Mex-
ico has rules regarding both research 
oversight and assisted reproduction; in-
deed, Zhang’s team may have violated 
Mexican federal regulations on medical 
research.15 Focusing solely on Mexico’s 
apparent failure to conform to the stan-
dards of ethics and regulation upheld in 
supposedly more developed countries 
deflects attention from the responsibili-
ties of scientists and reinforces biased 
attitudes about global ethical standards 
and the governance of science. We may 
draw a comparison here with gene edit-
ing and the ethical skepticism expressed 
toward the Chinese studies published 
on embryo gene editing. Such atti-
tudes reflect the perception, possibly 
unjustified, of a “Wild East” with in-
ferior ethical standards and inadequate 
regulation.16
Finally, Zhang’s work also illustrates 
a problem of justice with respect to reg-
ulatory capacity. Scientific tourism can 
impose an unfair oversight burden on 
countries where ethics and governance 
structures for these technologies are 
under development. Researchers who 
travel to take advantage of an already 
overloaded system are unjustifiably in-
creasing the burden of local oversight to 
further their own academic and other 
interests. If we consider that the scien-
tific brain drain (of human resources) 
or so-called biopiracy (of genetic or 
biological resources) are problems for 
global scientific justice, then siphoning 
off oversight resources by engaging in 
scientific tourism ought equally to be 
regarded as problematic. 
There is, though, one possible posi-
tive outcome of this event for Mexico. 
Spurred by worldwide attention to 
Zhang’s work, a national debate on as-
sisted reproduction that includes sci-
entists, stakeholders, and bioethicists 
might ensue, leading to an adequate 
regulatory framework that does not 
stifle scientific advancement. This pos-
sibility is remote at present due to Mex-
ico’s political climate, but it is one that 
we must try to promote.
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